eMed™ and Quest Diagnostics Collaborate to Offer Guided COVID-19 Rapid Antigen Testing to Help Employers Foster Safer Workplaces
August 11 2021 - 9:03AM
eMed™, a telehealth company democratizing healthcare through
digital-point-of-care solutions, and Quest Diagnostics (NYSE: DGX),
the world's leading provider of diagnostic information services,
are collaborating to bring clinician-guided rapid antigen testing
for COVID-19 to employers seeking to foster safer environments by
decreasing the risk of COVID-19 exposure in their workplaces.
Through the collaboration, the two companies will leverage the
BinaxNOW™ COVID-19 Ag Card Home Test, a self-administered, nasal
swab antigen test that provides results in 15 minutes. An eMed
Certified Guide supervises the testing process virtually,
confirming employee identity, overseeing proper sample collection,
and authenticating results during a telehealth visit.
Quest Diagnostics is the leading provider of employer population
health and workplace drug testing services, serving thousands of
employers across the United States. The company's services
range from lab and biometric screening to behavioral and mental
health interventions to telehealth, virtual care and flu
clinics.
Organizations are now able to have rapid test kits delivered
straight to employees’ homes. Individuals will receive their
validated results via a digital health pass on their smart device,
and employers will have access to a portal with consolidated
employee test results. Individuals who test positive will have the
option to undergo additional molecular testing through Quest
Diagnostics to confirm their positive result. Quest provides
gold-standard molecular diagnostic testing for COVID-19.
This solution uniquely offers employers the ability to
efficiently screen for COVID-19 using rapid antigen testing and
confirmatory molecular testing when necessary. Employees on
international travel may use the BinaxNOW™ COVID-19 Ag Card Home
Test during their trip to meet the CDC testing requirements for
reentry into the U.S. Because rapid antigen testing specimen
collection can be performed at home, or during business travel,
testing may help identify infected individuals before they are able
to enter the office, helping to reduce risk for other
employees.
“The eMed digital point-of-care platform for verified COVID-19
testing and results reporting is innovative in the health testing
and diagnostic services space, and that is our intent,” said Dr.
Patrice Harris, eMed Co-Founder and CEO. “We are thrilled to be
partnering with an industry leader like Quest Diagnostics to reach
more people and further mitigate the impact of COVID-19 with
convenient, accessible testing services, especially given the
emergence of worrisome variants.”
“Employers are eager to keep their workplaces as safe as
possible for their employees and their customers. While testing is
one way to do this, many employees are unsure how to implement a
testing program that will be effective and easy to execute,”
said Jay G. Wohlgemuth, M.D., Senior Vice President and Chief
Medical Officer, and head of Quest's Employer Population Health
business. “Our collaboration with eMed allows employers to offer
guided rapid antigen testing with access to gold-standard molecular
testing to confirm positive results, providing an unmatched level
of ease and quality, ensuring the likelihood of uptake by
employees.”
- This product has not been FDA cleared or approved; but has been
authorized by FDA under an EUA;
- This product has been authorized only for the detection of
proteins from SARS- CoV-2, not for any other viruses or pathogens;
and,
- This product is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked sooner.
About eMed
eMed (www.eMed.com) is a telehealth company democratizing
healthcare with a digital point-of-care platform that provides
fast, easy and affordable at-home health care testing, supervised
and guided online by eMed Certified Guides. We embrace quantitative
medicine to deliver prescribed tests and treatments directly to
individuals, driving better and more cost-effective health
outcomes.
About Quest Diagnostics Employer Population Health Quest
Diagnostics Employer Population Health is the leader in solutions
that help improve outcomes and costs for employers. With nationwide
lab access and insights from clinical data, Quest Diagnostics
provides health screenings and related population health solutions
and utilizes screening insights to help identify chronic disease
risks, connect employees to needed in-network care, and empower
better health. For more information,
visit www.QuestForHealth.com.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve
health outcomes. Derived from the world's largest database of
clinical lab results, our diagnostic insights reveal new avenues to
identify and treat disease, inspire healthy behaviors and improve
health care management. Quest annually serves one in three
adult Americans and half the physicians and hospitals in the United
States, and our nearly 50,000 employees understand that, in the
right hands and with the right context, our diagnostic insights can
inspire actions that transform lives. www.QuestDiagnostics.com.
# # #
eMed
media@emed.com
Margeaux Van Horn
Pinkston for eMed
703.722.8930
eMed@pinkston.co
Mallory McDonald
Pinkston for eMed
302.853.5344
eMed@pinkston.co
Kim Gorode
Quest Diagnostics
mediacontact@questdiagnostics.com
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Sep 2023 to Sep 2024